Immunohistochemical analyses suggested “CD56 (+), CgA (±), Syn (+), CK (AE1/AE3) (perinuclear punctate +), CK5/6 (–), CK7 (-), NapsinA (-), TTF-1 (+), Ki-67 (80%+), and programmed cell death receptor ligand-1 (PD-L1) <5%.” The genetic testing demonstrated the tumor mutational burden (TMB) of 1.82 and microsatellite stabilization (MSS). This evidence concerns the gene CD274 and neoplasm.